Quetiapine XR

ApprovedSmall molecule

AstraZeneca

Quetiapine XR is one of 266 small molecule programs targeting Specific Phobia. It is currently in Approved.

Indications

Total Trials

Active Trials

265

Competitors

Pipeline

Status by Indication[3][1]

Indication

Specific PhobiaActive, not recruiting

Panic DisorderActive, not recruiting

Postpartum DepressionActive, not recruiting

CognitionActive, not recruiting

AnxietyActive, not recruiting

Major Depressive DisorderActive, not recruiting

SchizophreniaActive, not recruiting

Bipolar DisorderActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

Anxiety DisorderActive, not recruiting

Specific PhobiaPhase 2

Active, not recruiting

Panic DisorderApproved

Active, not recruiting

Postpartum DepressionPreclinical

Active, not recruiting

CognitionPhase 3

Active, not recruiting

AnxietyApproved

Active, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

SchizophreniaPhase 3

Active, not recruiting

Bipolar DisorderApproved

Active, not recruiting

Generalized Anxiety DisorderPhase 3

Active, not recruiting

Anxiety DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Quetiapine XR

AstraZeneca

Approved

5 2

Celexa

AbbVie

Preclinical

4 3

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 4

Ozempic

Novo Nordisk

Preclinical

1 5

Resotran

Takeda

Preclinical

1 6

Zocor

OOrganon and Co

Preclinical

6 7

Depakote

Ibrance

Lunesta

3 10

Persantine

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia5 trials

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Completed·BBukwang Pharmaceutical·Phase 3·NCT03465787·210 enrolled

Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00954122·35 enrolled

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Completed· Otsuka logo

Otsuka·Phase 3·NCT04115319·305 enrolled

Show 2 more trials

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT00790192·488 enrolled

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT00789698·240 enrolled

Major Depressive Disorder4 trials

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04513912·757 enrolled

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT04338321·676 enrolled

Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder

Completed·SSunnybrook Health Sciences Centre·Phase 4·NCT00892463·26 enrolled

Show 1 more trial

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03321526·107 enrolled

Anxiety Disorder2 trials

Clinical Benefits of Seroquel XR in Anxiety Disorder

Unknown status·CCorporation de Recherche en Neuropsycho Pharmacologie de Quebec·Phase 3·NCT01672554·40 enrolled

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00389064·450 enrolled

Generalized Anxiety Disorder2 trials

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 3·NCT00671853·120 enrolled

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

Terminated·KKeming Gao·Phase 3·NCT00868374·23 enrolled

Depression2 trials

The Quietude Study: Quetiapine Use for Agitated Depression

Terminated·PPhysicians Research And Education Network·Phase 3·NCT01363310·250 enrolled

Brain Imaging of Quetiapine Response in Anxious Depression

Completed·IIndiana University School of Medicine·Phase 4·NCT00982345·20 enrolled

15 more indications

TIA2 trials

Quetiapine XR in Schizophrenic Patients

Terminated·HHannover Medical School·Phase 3·NCT01071135·5 enrolled

Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00600756·798 enrolled

Specific Phobia1 trial

Quetiapine in Specific Phobia

Completed·UUniversity Hospital Muenster·Phase 2·NCT00872716·60 enrolled

Cognition1 trial

The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression

Completed·UUniversity of British Columbia·Phase 3·NCT00517387·64 enrolled

Double-blind1 trial

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

Terminated·—·Phase 1·NCT00606541·55 enrolled

Bipolar Depression1 trial

Pediatric Bipolar Depression

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00811473·193 enrolled

Monotherapy1 trial

Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00789854·688 enrolled

Bipolar Disorder1 trial

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

Terminated·EEmory University·Phase 4·NCT00746421·32 enrolled

Postpartum Depression1 trial

Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolar Disorder (BD), Type II

Completed·—·N/A·NCT01527448·26 enrolled

Major Depression1 trial

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

Completed·UUniversity of Calgary·Phase 4·NCT02132286·57 enrolled

IPEX1 trial

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Completed·—·Phase 2·NCT00893841·96 enrolled

Agitation1 trial

Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry

Unknown status·BBayside Health·Phase 4·NCT00986167·72 enrolled

Alcohol Abstinence1 trial

The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence

Completed·SSubhajit Chakravorty·Phase 3·NCT00434876·22 enrolled

Panic Disorder1 trial

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

Completed·IIndiana University·Phase 4·NCT00619892·26 enrolled

Anxiety1 trial

Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients

Completed·LLoyola University·Phase 4·NCT00951483·91 enrolled

CAR1 trial

Schizophrenic Patients in Integrated Care

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT00681629·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for Quetiapine XR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Quetiapine XR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Quetiapine XR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Quetiapine XR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia5 trials

Major Depressive Disorder4 trials

Anxiety Disorder2 trials

Generalized Anxiety Disorder2 trials

Depression2 trials

TIA2 trials

Specific Phobia1 trial

Cognition1 trial

Double-blind1 trial

Bipolar Depression1 trial

Monotherapy1 trial

Bipolar Disorder1 trial

Postpartum Depression1 trial

Major Depression1 trial

IPEX1 trial

Agitation1 trial

Alcohol Abstinence1 trial

Panic Disorder1 trial

Anxiety1 trial

CAR1 trial

References

Drug Info

Quick Facts

Related News